ARS Pharmaceuticals(SPRY) - 2025 Q4 - Earnings Call Transcript

ARS Pharmaceuticals (NasdaqGM:SPRY) Q4 2025 Earnings call March 09, 2026 08:30 AM ET Company ParticipantsEric Karas - Chief Commercial OfficerJustin Chakma - Chief Business OfficerKathy Scott - CFOKevin Holder - Equity Research AssociateRichard Lowenthal - Co-Founder, President, and CEOConference Call ParticipantsAndreas Argyrides - Managing Director and Senior Biotech AnalystLachlan Hanbury-Brown - Biotech Equity Research AnalystNone - AnalystOperatorGood morning and welcome to ARS Pharmaceuticals' fourth ...